BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33334631)

  • 1. [Management of multirefractory immune thrombocytopenia].
    Mahévas M; Audia S; Viallard JF
    Rev Med Interne; 2021 Jan; 42(1):46-49. PubMed ID: 33334631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
    Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
    Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of refractory primary immune thrombocytopenia.
    Moulis G; Garabet L
    Br J Haematol; 2023 Oct; 203(1):112-118. PubMed ID: 38019080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F; Ruggeri M
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune thrombocytopenia: From pathogenesis to treatment].
    Audia S; Mahevas M; Bonnotte B
    Rev Med Interne; 2021 Jan; 42(1):16-24. PubMed ID: 32741715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epidemiology and pharmacoepidemiology of immune thrombocytopenia].
    Moulis G; Lapeyre-Mestre M; Adoue D; Sailler L
    Rev Med Interne; 2017 Jul; 38(7):444-449. PubMed ID: 28131440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of ITP and AIHA in CVID: A systematic literature review].
    Lacombe V; Lozac'h P; Orvain C; Lavigne C; Miot C; Pellier I; Urbanski G
    Rev Med Interne; 2019 Aug; 40(8):491-500. PubMed ID: 31101329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current approaches for the diagnosis and management of immune thrombocytopenia.
    Gafter-Gvili A
    Eur J Intern Med; 2023 Feb; 108():18-24. PubMed ID: 36424271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune thrombocytopenia.
    Bussel J; Cooper N; Boccia R; Zaja F; Newland A
    Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Thrombocytopenia in Children: Consensus and Controversies.
    Singh G; Bansal D; Wright NAM
    Indian J Pediatr; 2020 Feb; 87(2):150-157. PubMed ID: 31927692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Older Adults and Immune Thrombocytopenia: Considerations for the Clinician.
    Crickx E; Mahévas M; Michel M; Godeau B
    Clin Interv Aging; 2023; 18():115-130. PubMed ID: 36726813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content.
    Revilla N; Corral J; Miñano A; Mingot-Castellano ME; Campos RM; Velasco F; Gonzalez N; Galvez E; Berrueco R; Fuentes I; Gonzalez-Lopez TJ; de la Morena-Barrio ME; Gonzalez-Porras JR; Vicente V; Lozano ML
    Platelets; 2019; 30(6):743-751. PubMed ID: 30296193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controversies in the treatment of paediatric immune thrombocytopenia].
    Berrueco R; Dapena JL; Sebastián E; Sastre A
    An Pediatr (Engl Ed); 2018 Sep; 89(3):189.e1-189.e8. PubMed ID: 30033108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
    Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
    Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?
    Godeau B
    Br J Haematol; 2023 Oct; 203(1):86-95. PubMed ID: 37735555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging treatments for immune thrombocytopenia.
    Dou X; Yang R
    Expert Rev Hematol; 2019 Sep; 12(9):723-732. PubMed ID: 31237783
    [No Abstract]   [Full Text] [Related]  

  • 18. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
    Lv Y; Shi H; Liu H; Zhou L
    Front Immunol; 2022; 13():953716. PubMed ID: 36003388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
    Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.